trovafloxacin has been researched along with clarithromycin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Gikas, A; Psaroulaki, A; Spyridaki, I; Tselentis, Y; Vranakis, I | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Araujo, FG; Khan, AA; Polzer, RJ; Remington, JS; Slifer, T | 1 |
| Gikas, A; Kofterithis, D; Psaroulaki, A; Spyridaki, I; Tselentis, Y | 1 |
| Bouchillon, S; Johnson, J; Pontani, D; Washton, H | 1 |
| Debets-Ossenkopp, YJ; Herscheid, AJ; Kuipers, EJ; Kusters, JG; Pot, RG; Vandenbroucke-Grauls, CM | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Carabias, ML; Cervera, LA; entelles, ML; García-Navas, BL | 1 |
| Acampora, MD; Busman, TA; Notario, GF; Sokol, WN; Sullivan, JG | 1 |
| Carbon, C; Dunbar, L; Fogarty, C; Hagberg, L; Pullman, J; van Rensburg, DJ | 1 |
| Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
| Alexopoulos, LG; Cosgrove, BD; Griffith, LG; Hang, TC; Hendriks, BS; Lauffenburger, DA; Sorger, PK | 1 |
2 review(s) available for trovafloxacin and clarithromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Ketolides; Macrolides; Naphthyridines; Penicillins; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
2 trial(s) available for trovafloxacin and clarithromycin
| Article | Year |
|---|---|
A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Naphthyridines; Pneumonia; Prospective Studies; Radiography; Treatment Outcome | 2002 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
14 other study(ies) available for trovafloxacin and clarithromycin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Coxiella burnetii; Humans; Microbial Sensitivity Tests; Minocycline; Q Fever; Tigecycline; Vero Cells | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
Topics: Acute Disease; Administration, Oral; Animals; Anti-Infective Agents; Antiprotozoal Agents; Area Under Curve; Atovaquone; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Naphthoquinones; Naphthyridines; Rifabutin; Tissue Distribution; Toxoplasmosis, Animal | 1997 |
In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
Topics: Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Coxiella burnetii; Doxycycline; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin | 1998 |
Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Europe; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Pseudomonas aeruginosa; Respiratory System; Staphylococcus aureus; Streptococcus pneumoniae | 1998 |
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Utilization; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Netherlands; Tetracycline | 1999 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Community-Acquired Infections; Drug Resistance; Fluoroquinolones; Humans; Meningococcal Infections; Microbial Sensitivity Tests; Naphthyridines; Nasopharynx; Neisseria meningitidis; Respiratory Tract Infections; Rifampin; Time Factors | 2001 |
Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.
Topics: Anti-Infective Agents; Benzamides; Butadienes; Caspases; Cell Survival; Cells, Cultured; Clarithromycin; Cytokines; Diphenylamine; Fluoroquinolones; Hepatocytes; Humans; Mitogen-Activated Protein Kinases; Models, Biological; Naphthyridines; Nitriles; Phosphoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Time Factors | 2010 |